Physician
Henry Ford Pathology
Henry Ford Pathology was paid $6.91M by Medicaid between Jan 2018 and Dec 2024, across 158 billing codes. Its largest line is 87491, Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe — 9.4% of everything it billed.
33Billing provider infoHENRY FORD PATHOLOGY
DETROIT, MI 48202
DETROIT, MI 48202
33aNPI1851410005assigned 03/28/2007
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$6.91M
24GClaims662,910
24DCodes billed158
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Michigan
Rank by total paid#1 of 51
Median peer was paid$161K
This provider vs. median43×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,462 | $64K | |
| 2019 | 93,141 | $544K | |
| 2020 | 73,581 | $710K | |
| 2021 | 116,272 | $1.17M | |
| 2022 | 133,708 | $1.61M | |
| 2023 | 132,986 | $1.61M | |
| 2024incomplete | 101,760 | $1.20M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 9.4% | 27,026 | 26,376 | $649K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 8.9% | 25,184 | 24,578 | $613K |
| 84443 | Thyroid stimulating hormone (TSH) | 5.1% | 32,720 | 31,777 | $354K |
| 80061 | Lipid panel | 4.1% | 33,994 | 33,379 | $280K |
| 80053 | Comprehensive metabolic panel | 3.8% | 38,122 | 36,740 | $261K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3.6% | 15,959 | 15,672 | $249K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.3% | 45,238 | 43,549 | $228K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.3% | 5,883 | 5,724 | $226K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.1% | 1,942 | 1,876 | $217K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 3.0% | 9,008 | 8,711 | $208K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 3.0% | 8,405 | 8,184 | $207K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.7% | 12,755 | 12,485 | $187K |
146 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.5% | 2,764 | $171K |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.4% | 27,339 | $163K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 2.2% | 7,709 | $149K |
| 86803 | 1.7% | 12,908 | $121K | |
| 86780 | 1.7% | 13,413 | $115K | |
| 88142 | 1.5% | 8,311 | $101K | |
| 87536 | 1.4% | 1,778 | $100K | |
| 84439 | 1.4% | 16,378 | $98K | |
| 81513 | 1.4% | 953 | $95K | |
| 82607 | 1.3% | 10,586 | $91K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.3% | 3,313 | $87K |
| 87481 | 1.2% | 2,909 | $83K | |
| 84702 | 1.1% | 8,225 | $79K | |
| 87808 | 1.1% | 7,681 | $79K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.1% | 15,368 | $78K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.0% | 13,118 | $71K |
| 84403 | <1% | 3,731 | $62K | |
| 85027 | <1% | 12,917 | $54K | |
| 87340 | <1% | 7,651 | $50K | |
| 83970 | <1% | 2,097 | $48K | |
| 87511 | <1% | 2,036 | $47K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 28,816 | $47K |
| 82728 | <1% | 5,286 | $45K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,296 | $43K |
| 83550 | <1% | 6,300 | $36K | |
| 87634 | <1% | 716 | $36K | |
| 87081 | <1% | 8,003 | $34K | |
| 82746 | <1% | 3,639 | $34K | |
| 80074 | <1% | 1,216 | $33K | |
| 82670 | <1% | 1,768 | $32K | |
| 86480 | <1% | 769 | $31K | |
| 83001 | <1% | 2,386 | $30K | |
| 87210 | <1% | 7,677 | $30K | |
| 86850 | <1% | 4,863 | $30K | |
| 86762 | <1% | 3,877 | $29K | |
| 83540 | <1% | 6,752 | $28K | |
| 84146 | <1% | 2,219 | $28K | |
| 83735 | <1% | 6,329 | $27K | |
| 86360 | <1% | 849 | $25K | |
| 82570 | <1% | 7,315 | $25K | |
| 82105 | <1% | 2,174 | $22K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,769 | $21K |
| 83002 | <1% | 1,761 | $21K | |
| 82043 | <1% | 5,353 | $19K | |
| 82947 | <1% | 7,194 | $18K | |
| 86003 | <1% | 360 | $18K | |
| 84481 | <1% | 1,642 | $17K | |
| 84450 | <1% | 5,154 | $17K | |
| 84460 | <1% | 5,195 | $17K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 306 | $16K |
| 82248 | <1% | 4,290 | $16K | |
| 86769 | <1% | 545 | $16K | |
| 87186 | <1% | 2,797 | $16K | |
| 83655 | <1% | 1,745 | $15K | |
| 86235 | <1% | 350 | $15K | |
| 86140 | <1% | 4,097 | $14K | |
| 86039 | <1% | 2,207 | $14K | |
| 88141 | <1% | 993 | $13K | |
| 83020 | <1% | 1,501 | $13K | |
| 81001 | <1% | 6,001 | $12K | |
| 84153 | <1% | 1,226 | $12K | |
| 83013 | <1% | 271 | $12K | |
| 85610 | <1% | 4,120 | $11K | |
| 84480 | <1% | 1,255 | $11K | |
| 82565 | <1% | 3,119 | $10K | |
| 87077 | <1% | 1,824 | $10K | |
| 86255 | <1% | 934 | $10K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 226 | $9K |
| 86376 | <1% | 1,049 | $9K | |
| 82550 | <1% | 2,157 | $9K | |
| 83880 | <1% | 356 | $9K | |
| 86900 | <1% | 4,524 | $9K | |
| 86200 | <1% | 1,037 | $8K | |
| 86901 | <1% | 4,524 | $8K | |
| 82977 | <1% | 1,568 | $8K | |
| 85652 | <1% | 4,333 | $7K | |
| 86696 | <1% | 709 | $7K | |
| 84550 | <1% | 2,607 | $7K | |
| 87088 | <1% | 1,356 | $7K | |
| 86787 | <1% | 1,050 | $7K | |
| 86706 | <1% | 965 | $7K | |
| 83516 | <1% | 417 | $7K | |
| 84100 | <1% | 2,314 | $6K | |
| 87522 | Neg quan hep c or qual rna | <1% | 268 | $6K |
| 86431 | <1% | 1,739 | $6K | |
| 85730 | <1% | 1,654 | $6K | |
| 82274 | <1% | 594 | $6K | |
| 86160 | <1% | 359 | $6K | |
| 85007 | <1% | 2,200 | $6K | |
| 86695 | <1% | 758 | $5K | |
| 84520 | <1% | 1,969 | $5K | |
| 82627 | <1% | 339 | $5K | |
| 82784 | <1% | 355 | $5K | |
| 80076 | <1% | 822 | $4K | |
| 80051 | <1% | 1,060 | $4K | |
| 84156 | <1% | 2,043 | $4K | |
| 81003 | <1% | 2,734 | $4K | |
| 83615 | <1% | 1,028 | $4K | |
| 87529 | <1% | 123 | $4K | |
| 83525 | <1% | 465 | $4K | |
| 83690 | <1% | 922 | $4K | |
| 87420 | <1% | 357 | $4K | |
| 84144 | <1% | 257 | $4K | |
| 87147 | <1% | 975 | $3K | |
| 83721 | <1% | 434 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 59 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 92 | $2K |
| 86694 | <1% | 255 | $2K | |
| 86800 | <1% | 179 | $2K | |
| 82465 | <1% | 656 | $2K | |
| 82533 | <1% | 169 | $2K | |
| 82310 | <1% | 527 | $2K | |
| 86593 | <1% | 599 | $2K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 64 | $2K |
| 88342 | <1% | 46 | $2K | |
| 86146 | <1% | 25 | $1K | |
| 86147 | <1% | 25 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 36 | $1K |
| 85045 | <1% | 442 | $1K | |
| 87631 | <1% | 12 | $869.62 | |
| 87070 | <1% | 119 | $733.61 | |
| 82040 | <1% | 160 | $556.77 | |
| 85379 | <1% | 85 | $545.32 | |
| 84436 | <1% | 111 | $525.87 | |
| 86592 | <1% | 302 | $500.00 | |
| 83014 | <1% | 87 | $487.23 | |
| 80305 | <1% | 67 | $479.99 | |
| 86708 | <1% | 54 | $440.72 | |
| 85613 | <1% | 65 | $436.74 | |
| 87205 | <1% | 141 | $422.10 | |
| 83718 | <1% | 67 | $402.11 | |
| 82652 | <1% | 24 | $400.13 | |
| 82330 | <1% | 26 | $300.01 | |
| 82085 | <1% | 27 | $192.54 | |
| 83520 | <1% | 13 | $141.05 | |
| 82150 | <1% | 25 | $119.04 | |
| 86765 | <1% | 34 | $117.64 | |
| 85060 | <1% | 53 | $98.49 | |
| 81015 | <1% | 42 | $94.41 | |
| 84484 | <1% | 14 | $88.20 | |
| 86225 | <1% | 16 | $82.99 | |
| G0124 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | <1% | 246 | $78.75 |
| 86735 | <1% | 12 | $68.95 | |
| 84075 | <1% | 49 | $66.39 | |
| 80050 | General health panel | <1% | 545 | $20.00 |
| 84270 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBALDWIN, ADAM (DIRECTOR)